75% First-Pass Success in M1 Occlusions: Key Takeaways from the Perfuze-SNIS Webinar

On May 4, 2026, Perfuze and SNIS co-hosted an expert webinar featuring Dr. David Fiorella, Dr. Sunil

Sheth, and Dr. Tarun Bhalla and one number drove the conversation: 75%. That's the rate of M1

occlusion cases achieving TICI 2c-3 reperfusion on the first pass with the Millipede88® Catheter in the

MARRS Study1.

The Design Difference

Traditional aspiration catheters can kink and ovalize in tortuous anatomy — reducing lumen size when

aspiration matters most. The Millipede catheter’s corrugated structure and ePTFE liner is designed to

allow the catheter to bend without compromising lumen integrity2, maintaining consistent aspiration

power through even the most challenging anatomy.

The Data

Results from the MARRS trial with the Millipede88® Aspiration Catheter:

• 75% of M1 cases achieved TICI 2c-3 on the first pass1

• 96% delivery success for the Millipede88 Aspiration Catheter to the target3

• 89% achieved substantial reperfusion (TICI ≥2b) within three passes4

• 2.3% symptomatic ICH4

• Consistent first pass effect in top enrolling sites vs all others5

The Bottom Line

First-pass success is becoming the standard by which stroke programs are measured — clinically and

operationally. Fewer passes mean fewer devices, and potentially better patient outcomes6. The

Millipede88® System was built for exactly that standard.

References:

1 MARRS data on file (CLIN087). Per-Protocol Population, M1 occlusions, Millipede88 used on first pass (n=56).

2 In-vitro testing. LN2402-25-02. Catheter Lumen Patency Evaluation.

3 MARRS data on file (TR336). Deliverability of Millipede System in MARRS Study.

4 MARRS data on file (CLIN087). Intent-To-Treat Population.

5 MARRS data on file (PI25-010). Post-hoc analysis, Per-Protocol Population, Millipede88 used on first pass.

6 Zaidat et al., 2021. Journal of NeuroInterventional Surgery, 13:1117–1123.